- Report
- February 2024
- 120 Pages
Global
From €4231EUR$4,750USD£3,661GBP
- Report
- April 2023
- 110 Pages
Global
From €4231EUR$4,750USD£3,661GBP
- Report
- April 2023
- 119 Pages
Global
From €4231EUR$4,750USD£3,661GBP
- Report
- May 2026
- 151 Pages
Australia
From €4320EUR$4,850USD£3,738GBP
- Report
- May 2026
- 154 Pages
Germany
From €4320EUR$4,850USD£3,738GBP
- Report
- May 2026
- 157 Pages
Italy
From €4320EUR$4,850USD£3,738GBP
- Report
- May 2026
- 160 Pages
Mexico
From €4320EUR$4,850USD£3,738GBP
- Report
- May 2026
- 166 Pages
Spain
From €4320EUR$4,850USD£3,738GBP
- Report
- May 2026
- 167 Pages
Thailand
From €4320EUR$4,850USD£3,738GBP
- Report
- May 2026
- 169 Pages
United Kingdom
From €4320EUR$4,850USD£3,738GBP
- Report
- February 2026
- 150 Pages
Germany
From €4320EUR$4,850USD£3,738GBP
- Report
- July 2023
- 290 Pages
Global
From €3206EUR$3,600USD£2,775GBP
- Report
- April 2023
- 326 Pages
Global
From €3206EUR$3,600USD£2,775GBP
- Report
- November 2022
- 206 Pages
Global
From €3206EUR$3,600USD£2,775GBP
- Report
- May 2022
- 188 Pages
Global
From €3206EUR$3,600USD£2,775GBP
- Report
- February 2022
- 185 Pages
Global
From €3206EUR$3,600USD£2,775GBP
- Report
- November 2022
- 154 Pages
Global
From €4453EUR$5,000USD£3,854GBP
- Report
- April 2021
China
From €2316EUR$2,600USD£2,004GBP
- Report
- November 2020
- 450 Pages
Global
From €4364EUR$4,900USD£3,776GBP
- Report
- September 2020
- 700 Pages
Global
From €4364EUR$4,900USD£3,776GBP

Pembrolizumab is a type of oncology drug used to treat certain types of cancer. It is a monoclonal antibody, which works by targeting and blocking a protein called PD-1, which is found on the surface of some cancer cells. This helps the body's immune system to recognize and attack the cancer cells. Pembrolizumab is used to treat a variety of cancers, including melanoma, non-small cell lung cancer, head and neck cancer, Hodgkin lymphoma, and urothelial carcinoma. It is also used in combination with other drugs to treat certain types of advanced or metastatic cancers.
Pembrolizumab is approved by the US Food and Drug Administration (FDA) and is available in the US and other countries. It is typically administered intravenously, and the dosage and duration of treatment depend on the type and stage of cancer being treated.
Some companies in the Pembrolizumab market include Merck & Co., Inc., Bristol-Myers Squibb, AstraZeneca, and Roche. Show Less Read more